# An Evaluation of Three Doses of NS 2330 in Patients With Mild to Moderate Dementia of the Alzheimer's Type

> **NCT00153010** · PHASE2 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 430 (actual)

## Conditions studied

- Alzheimer Disease

## Interventions

- **DRUG:** NS 2330 (Tesofensine)

## Key facts

- **NCT ID:** NCT00153010
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-02
- **Primary completion:** 2005-03
- **Final completion:** —
- **Target enrollment:** 430 (ACTUAL)
- **Last updated:** 2013-10-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00153010

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00153010, "An Evaluation of Three Doses of NS 2330 in Patients With Mild to Moderate Dementia of the Alzheimer's Type". Retrieved via AI Analytics 2026-07-01 from https://api.ai-analytics.org/clinical/NCT00153010. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*